Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

Special Report

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

Clinical Forums Recaps

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Treatment Landscape Evolutions

Subscribe

Articles

Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.

Oral sulopenem was approved by the FDA in October 2024 for the management of uUTIs. 

Phase 3 data of oral sulopenem for uUTIs published in NEJM Evidence

Detalimogene is currently under evaluation in the pivotal phase 1/2 LEGEND trial.

FDA grants RMAT designation to detalimogene voraplasmid for high-risk NMIBC

The approach was associated with a 30% decrease in PSMA uptake by the salivary glands without compromising the treatment’s efficacy.

Botulinum toxin reduces PSMA therapy-related salivary gland toxicity

 is compliance officer and medical director of coding and reimbursement, United Urology Group and Chesapeake Urology, in Towson, Maryland.

"We have received numerous complaints about the PA and predetermination process. We all wish we could answer this differently and definitively," write Jonathan Rubenstein, MD, and Mark Painter.

The C1769 prior authorization puzzle: A billing challenge

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times – News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

Advancements in Imaging and Diagnosing Kidney Cancers: The Future Role of PET Imaging Agents

, discuss how NMIBC management has evolved significantly with new FDA approvals including pembrolizumab, nogapendekin alfa, and nadofaragene for BCG-unresponsive disease. Novel therapies in development include sustained-release platforms and immunotherapies.

Innovative Immunological and Target Therapies for NMIBC: Recent Clinical Trial Data Shaping the Future

Androgen Receptor-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Treatment Selection, Sequencing, and Considerations

A panel of urologic and oncologic experts provide comprehensive insights on optimal utilization of androgen deprivation therapy in patients with prostate cancer, highlighting the evolving treatment landscape and recent clinical trial data.

Optimizing Androgen Deprivation Therapy in Prostate Cancer: Evidence, Best Practices, and New Frontiers

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, discuss key conversation points surrounding high-risk BCG-unresponsive NMIBC as presented at ASCO 2024 in Chicago, Illinois.

Deep Data Dive: Highlights From ASCO 2024 on the Treatment of High-Risk BCG-Unresponsive NMIBC

Neal Shore, MD, FACS, and Brian M. Shuch, MD, have a comprehensive discussion on the evolving imaging and diagnostic landscape in kidney cancer, highlighting emerging PET imaging agents.

Advances in Imaging and Diagnosing Kidney Cancers: The Emerging Role of PET Imaging Agents

Matthew Smith, MD, PhD, and Brian T. Helfand, MD, have a comprehensive discussion on the treatment of patients with prostate cancer, highlighting the treatment of nonmetastatic CRPC and metastatic HSPC and the role of AR pathway inhibitors.

Emerging Treatment Strategies in Advanced Prostate Cancer: The Role for ARPIs

Christopher M. Pieczonka, MD and Jose De La Cerda, MD, MPH engage in a comprehensive discussion on the nuances of abiraterone formulations for treating metastatic castration-resistant prostate cancer (mCRPC). They explore patient assessment, treatment considerations for special populations, and clinical practice management tailored to the diverse needs of patients with mCRPC.

Urology Practice Management Considerations & Treatment Selection for Special Populations with Metastatic CRPC

Michelle Semins, MD, and Seth Bechis, MD, explore recent advancements in treating urinary stones, focusing on the significance of intrarenal pressure (IRP), its effect on patient outcomes, and methods to decrease elevated IRP.

The Evolving Role of IRP Monitoring in the Treatment and Management of Urinary Stones

Experts David Morris, MD, FACS, and Benjamin Garmezy, MD, share a dynamic discussion on the respective roles of combination therapy and multidisciplinary care in the current treatment landscape of advanced prostate cancer.

A Collaborative Approach to the Treatment and Management of Advanced Prostate Cancer

Key opinion leaders discuss the latest PSMA-PET imaging updates for prostate cancer and consider how real-world practice has evolved.

Clinical Updates on PSMA-PET Imaging for Prostate Cancer

This Uroview features discussion between Dr. Alexandra Rogers and Dr. Scott MacDiarmid about current and emerging treatments for overactive bladder, with a focus on implantable tibial nerve stimulation devices in this space.

Implantable Tibial Nerve Stimulation Devices for Treatment of Overactive Bladder

Steven Finkelstein, MD, DABR, FACRO, and Louis J. Mazzarelli, MD, react to the article, “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Pernthaler B, et al.

18F-Fluciclovine Versus 68Ga-PSMA-11 Imaging for Prostate Cancer Biochemical Recurrence

The Role of Androgen Receptor Inhibitors in the Management of Advanced Prostate Cancer

Two experts in urology provide a discussion on currently available screening and risk assessment tools in prostate cancer and emphasize the importance of early detection.

The Role of Liquid Biomarker for Early Detection of Prostate Cancer

Analysis of Gallium-68 PSMA 9 (prostate-specific membrane antigen) targeted PET (positron emission tomography) imaging and its impact on staging and prostate cancer.

Gallium-68 PSMA Targeted PET Imaging in Prostate Cancer: Staging and Outcomes 

Specialists in urology discuss the significance of germline testing in prostate cancer.

Genetic Testing in Prostate Cancer